Royalties was Halozyme Therapeutics’s largest product and service line in fiscal 2025, bringing in $867.84M of $1.40B (62%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Royalties | $360.48M | $447.87M | $570.99M | $867.84M | ||||||
| Revenues Under Collaborative Agreements | — | — | — | — | ||||||
| Product Sales, Net | — | — | — | — | ||||||
| Proprietary Product Sales | $72.85M | $130.83M | $166.62M | $194.61M | ||||||
| Sale Of Proprietary Products | — | — | — | — | ||||||
| Bulk Rhuph20 Sales | $82.08M | $115.44M | $86.33M | $133.02M | ||||||
| Sales Of Bulk Rhuph20 | — | — | — | — | ||||||
| Event-Based Development & Regulatory Milestones And Other Fees | $59.00M | $69.00M | $72.50M | $47.00M | ||||||
| Device Partnered Product Sales | $36.10M | $54.58M | $50.54M | $48.81M | ||||||
| Sales-Based Milestones | $10.00M | — | $30.00M | $70.00M | ||||||
| Event-Based Development Milestones & Regulatory Milestone And Other Fees | — | — | — | — | ||||||
| Upfront License & Target Nomination Fees | $30.00M | $2.00M | $27.00M | $18.47M | ||||||
| Sales Of Hylenex | — | — | — | — | ||||||
| Device Licensing & Development Revenue | $9.61M | $9.53M | $11.34M | $16.86M | ||||||
| Research & Development Services | — | — | — | — | ||||||
| Sales Of Enhanze Drug Product | — | — | — | — | ||||||
| Total | $660.12M | $829.25M | $1.02B | $1.40B |
Halozyme Therapeutics brought in $1.40B from its eight product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 37.6% from $1.02B in fiscal 2024. Royalties was the largest at $867.84M (62.1%), ahead of Proprietary Product Sales at $194.61M (13.9%) and Bulk Rhuph20 Sales at $133.02M (9.5%). The other five lines brought in $201.14M combined.
Compared with fiscal 2024, Sales-Based Milestones grew fastest, up 133.3% to $70.00M, while Event-Based Development & Regulatory Milestones And Other Fees fell the most, down 35.2% to $47.00M. From fiscal 2022 to 2025, combined revenue from these lines grew from $660.12M to $1.40B, a compound annual growth rate of 28.4%. Royalties' share of the total rose from 54.6% to 62.1%.
United States was Halozyme Therapeutics’s largest revenue line in fiscal 2025, bringing in $822.98M of $1.40B (59%).
| Concentration Risk Type | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| United States | $437.99M | $587.20M | $690.46M | $822.98M | |||||
| Switzerland | $166.84M | $149.02M | $212.39M | $276.41M | |||||
| Belgium | $2.09M | $58.35M | $84.01M | $217.52M | |||||
| Japan | $47.94M | $15.10M | $18.94M | $46.37M | |||||
| Ireland | — | — | — | — | |||||
| All Other Foreign | $5.26M | $19.58M | $9.53M | $33.33M | |||||
| Total | $660.12M | $829.25M | $1.02B | $1.40B |
Halozyme Therapeutics brought in $1.40B from its five revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 37.6% from $1.02B in fiscal 2024. United States was the largest at $822.98M (58.9%), ahead of Switzerland at $276.41M (19.8%) and Belgium at $217.52M (15.6%). The other two revenue lines brought in $79.71M combined.
Compared with fiscal 2024, All Other Foreign grew fastest, up 249.9% to $33.33M. Every revenue line above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these revenue lines grew from $660.12M to $1.40B, a compound annual growth rate of 28.4%. United States' share of the total fell from 66.4% to 58.9%.
Halozyme Therapeutics (HALO) reports its revenue by product and service and by concentration risk type. In fiscal 2025, Royalties was its largest product and service line, bringing in $867.84M (62.1% of the total), followed by Proprietary Product Sales at $194.61M (13.9%).
Royalties was Halozyme Therapeutics' largest product and service line in fiscal 2025, bringing in $867.84M, or 62.1% of the $1.40B total across its eight product and service lines.
United States was Halozyme Therapeutics' largest revenue line in fiscal 2025, bringing in $822.98M, or 58.9% of the $1.40B total across its five revenue lines.
Among Halozyme Therapeutics' product and service lines that make up at least 2% of revenue, Sales-Based Milestones grew fastest in fiscal 2025, up 133.3% from $30.00M to $70.00M.
Every figure comes from Halozyme Therapeutics' annual financial filings, as reported. Each line keeps the name Halozyme Therapeutics gives it, and years follow its fiscal calendar.
Halozyme Therapeutics' revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.